Phentolamine prevents the somatostatin-mediated inhibition of pancreatic glucagon secretion.
This study was undertaken to assess the role of alpha-adrenergic receptors in the somatostatin-mediated inhibition of pancreatic glucagon secretion. In dogs, somatostatin inhibited the pancreatico-duodenal vein output of glucagon. During an infusion of the alpha-adrenergic blocking agent phentolamine, somatostatin did not significantly inhibit the output of glucagon. Thus, alpha-adrenergic mechanisms appear to influence the ability of somatostatin to decrease pancreatic glucagon secretion.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004285:Dogs; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010646:Phentolamine / Q000494:pharmacology*; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D013004:Somatostatin / Q000494:pharmacology*
D001786:Blood Glucose; D011942:Receptors, Adrenergic, alpha; D013004:Somatostatin; D005934:Glucagon; D010646:Phentolamine